biostudies-literatureZhao LPNational Institute of Allergy and Infectious DiseasesNIAID NIH HHSNIMH NIH HHSe0226803https://www.ebi.ac.uk/biostudies/studies/S-EPMC6992005biostudies-literatureUnknown15(1)<h4>Background</h4>HIV vaccine trials routinely measure multiple vaccine-elicited immune responses to compare regimens and study their potential associations with protection. Here we employ unsupervised learning tools facilitated by a bidirectional power transformation to explore the multivariate binding antibody and T-cell response patterns of immune responses elicited by two pox-protein HIV vaccine regimens. Both regimens utilized a recombinant canarypox vector (ALVAC-HIV) prime and a bivalent recombinant HIV-1 Envelope glycoprotein 120 subunit boost. We hypothesized that within each trial, there were participant subgroups sharing similar immune responses and that their frequencies differed across trials.<h4>Methods and findings</h4>We analyzed data from three trials-RV144 (NCT00223080),PloS oneLandscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.PMC6992005UM1 AI069469UM1AI068618UM1 AI068635R21 MH083308UM1AI068614UM1 AI068614R01 AI122991UM1AI068635R37 AI054165UM1 AI068618UM1 AI069453Innes CMoodie ZRerks-Ngarm SRouphael NZhao MJanes HEPitisuttithum PFong YZhao LPCohen KWMcElrath MJFiore-Gartland AYates NLDintwe OGilbert PBLazarus ECorey LGray GEFrahm NFleurs LSeaton KEHuang YDe Rosa SCGarrett NRobb MLNitayaphan SMichael NLTomaras GDCarpp LNfalseLandscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.<h4>Background</h4>HIV vaccine trials routinely measure multiple vaccine-elicited immune responses to compare regimens and study their potential associations with protection. Here we employ unsupervised learning tools facilitated by a bidirectional power transformation to explore the multivariate binding antibody and T-cell response patterns of immune responses elicited by two pox-protein HIV vaccine regimens. Both regimens utilized a recombinant canarypox vector (ALVAC-HIV) prime and a bivalent recombinant HIV-1 Envelope glycoprotein 120 subunit boost. We hypothesized that within each trial, there were participant subgroups sharing similar immune responses and that their frequencies differed across trials.<h4>Methods and findings</h4>We analyzed data from three trials-RV144 (NCT00223080),2020-01-01T00:00:00Z20202026-05-07T21:58:26.858Z2020-05-22T10:36:10ZS-EPMC69920053199973610.1371/journal.pone.0226803